A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder
Public ClinicalTrials.gov record NCT05193409. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of BNC210 Compared to Placebo for the Acute Treatment of Social Anxiety Disorder
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the effects of an acute dose of BNC210 compared to placebo on reducing anxiety provoked by a speaking challenge and measured using the Subjective Units of Distress Scale (SUDS) in patients with Social Anxiety Disorder (SAD).
Study identification
- NCT ID
- NCT05193409
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 151 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 1, 2022
- Primary completion
- Oct 9, 2022
- Completion
- Oct 16, 2022
- Last update posted
- Mar 17, 2025
2022
United States locations
- U.S. sites
- 15
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| PREVAIL Study Clinical Trial Site | Beverly Hills | California | 90210 | — |
| PREVAIL Study Clinical Trial Site | Encino | California | 91316 | — |
| PREVAIL Study Clinical Trial Site | Glendale | California | 91204 | — |
| PREVAIL Study Clinical Trial Site | New Haven | Connecticut | 33122 | — |
| PREVAIL Study Clinical Trial Site | Lauderhill | Florida | 33319 | — |
| PREVAIL Study Clinical Trial Site | Miami | Florida | 33122 | — |
| PREVAIL Study Clinical Trial Site | Miami Lakes | Florida | 33016 | — |
| PREVAIL Study Clinical Trial Site | Decatur | Georgia | 30030 | — |
| PREVAIL Study Clinical Trial Site | Prairie Village | Kansas | 66208 | — |
| PREVAIL Study Clinical Trial Site | Boston | Massachusetts | 02114 | — |
| PREVAIL Study Clinical Trial Site | Princeton | New Jersey | 08540 | — |
| PREVAIL Study Clinical Trial Site | Brooklyn | New York | 11229 | — |
| PREVAIL Study Clinical Trial Site | Charlotte | North Carolina | 28211 | — |
| PREVAIL Study Clinical Trial Site | Cincinnati | Ohio | 45212 | — |
| PREVAIL Study Clinical Trial Site | Draper | Utah | 84020 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05193409, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 17, 2025 · Synced Sep 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05193409 live on ClinicalTrials.gov.